Literature DB >> 19478295

Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial.

Nikolaj Kunøe1, Philipp Lobmaier, John Kåre Vederhus, Bjørg Hjerkinn, Solfrid Hegstad, Michael Gossop, Øistein Kristensen, Helge Waal.   

Abstract

BACKGROUND: Naltrexone has considerable potential in helping to prevent relapse in heroin dependency. A longer-lasting formulation for naltrexone treatment is desirable to further reduce non-adherence and relapse during treatment of opiate dependence. AIMS: To evaluate the safety and effectiveness of a 6-month naltrexone implant in reducing opioid use after in-patient treatment.
METHOD: A group of 56 abstinence-oriented patients who completed in-patient treatment for opioid dependence were randomly and openly assigned to receive either a 6-month naltrexone implant or their usual aftercare. Drug use and other outcomes were assessed at 6-month follow-up.
RESULTS: Patients receiving naltrexone had on average 45 days less heroin use and 60 days less opioid use than controls in the 180-day period (both P<0.05). Blood tests showed naltrexone levels above 1 ng/ml for the duration of 6 months. Two patients died, neither of whom had received an implant.
CONCLUSIONS: Naltrexone implant treatment safely and significantly reduces opioid use in a motivated population of patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19478295     DOI: 10.1192/bjp.bp.108.055319

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  22 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

Review 2.  Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Authors:  Evgeny Krupitsky; Edwin Zvartau; George Woody
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

3.  Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.

Authors:  Evgeny Krupitsky; Edwin Zvartau; Elena Blokhina; Elena Verbitskaya; Valentina Wahlgren; Marina Tsoy-Podosenin; Natalia Bushara; Andrey Burakov; Dmitry Masalov; Tatyana Romanova; Arina Tyurina; Vladimir Palatkin; Tatyana Yaroslavtseva; Anna Pecoraro; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-19       Impact factor: 3.829

Review 4.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

5.  Multiple mechanisms underlying the long duration of action of thienorphine, a novel partial opioid agonist for the treatment of addiction.

Authors:  Gang Yu; Shu-Hui Li; Meng-Xun Cui; Ling-Di Yan; Zheng Yong; Pei-Lan Zhou; Rui-Bin Su; Ze-Hui Gong
Journal:  CNS Neurosci Ther       Date:  2013-12-16       Impact factor: 5.243

Review 6.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

Review 7.  Opioid dependence.

Authors:  K Thyarappa Praveen; Fergus Law; Jacinta O'Shea; Jan Melichar
Journal:  BMJ Clin Evid       Date:  2011-09-20

Review 8.  Antagonist Models for Relapse Prevention and Reducing HIV Risk.

Authors:  George E Woody; Evgeny Krupitsky; Edwin Zvartau
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-27       Impact factor: 4.147

Review 9.  A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?

Authors:  Breanne E Biondi; Xiaoying Zheng; Cynthia A Frank; Ismene Petrakis; Sandra A Springer
Journal:  Am J Addict       Date:  2020-04-29

Review 10.  Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

Authors:  Jeanette M Tetrault; David A Fiellin
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.